Changeflow GovPing Healthcare Patent Extension Comment Period
Priority review Consultation Added Consultation

Patent Extension Comment Period

Email

Summary

FDA has opened a 60-day public comment period for a patent extension matter under docket FDA-2025-E-3074-0006. The agency is seeking stakeholder input on the EMRELIS patent extension proposal. Interested parties may submit comments through Regulations.gov.

What changed

FDA has initiated a public consultation inviting comments on a patent extension matter (EMRELIS). The comment period provides 60 days for stakeholders to submit feedback. This is a standard notice-and-comment rulemaking procedure under the Hatch-Waxman Act framework.

Pharmaceutical companies, drug manufacturers, and patent holders should review the proposed patent extension and submit relevant comments before the deadline. Failure to participate in the comment period may result in missed opportunities to influence the agency's determination. Comments must be submitted through Regulations.gov.

What to do next

  1. Review the patent extension proposal under docket FDA-2025-E-3074-0006
  2. Submit comments before the 60-day deadline
  3. Include any supporting data or legal arguments in the comment submission

Archived snapshot

Apr 3, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

Write a Comment

Commenter's Checklist
Public Comments on Federal Regulations

Comment *

5000

What is your comment about?

Attach Files

You can attach up to 20 files, but each file cannot exceed 10MB. Valid file types include: bmp, docx, gif, jpg, jpeg, pdf, png, pptx, rtf, sgml, tif, tiff, txt, wpd, xlsx, xml. Drop files here or Browse...

Email Address

Opt to receive email confirmation of submission and tracking number?
If you choose to identify as Anonymous, the option to receive an email confirmation will not be displayed. (We will never post the email address entered in the field above on Regulations.gov nor share it with anyone else.)

Tell us about yourself! I am... *

(Select an identity below)

An Individual

Yourself or another person whom
you represent with their consent

An Organization

A company, organization,
or government agency

Anonymous

A person who does not want their name
associated with the comment

Note: If you choose to identify as Anonymous, the option to enter your email address for submission confirmation is not available.

reCAPTCHA *

Solve with 2Captcha Do not submit personally identifiable information through this form. Any personally identifiable information (e.g., name, address, phone number) included in the comment form or in an attachment may be publicly disclosed in a docket or on the Internet (via Regulations.gov, a federal agency website, or a third-party, non-government website with access to publicly-disclosed data on Regulations.gov). By submitting a comment, you agree to the terms of participation and privacy notice.

Submit Comment

Please see the Privacy Notice and User Notice regarding comment submission.

Any information (e.g., personal or contact) you provide on this comment form or in an attachment may be publicly disclosed and searchable on the Internet and in a paper docket and will be provided to the Department or Agency issuing the notice. To view any additional information for submitting comments, such as anonymous or sensitive submissions, refer to the Privacy Notice and User Notice, the Federal Register notice on which you are commenting, and the Web site of the Department or Agency.

Get daily alerts for Regs.gov: Food and Drug Administration

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from FDA.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
FDA
Instrument
Consultation
Legal weight
Non-binding
Stage
Consultation
Change scope
Minor
Document ID
FDA-2025-E-3074-0006
Docket
FDA-2025-E-3074-0006

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers Patients
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Drug Approval Patent Extension
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Legal
Topics
Intellectual Property Healthcare

Get alerts for this source

We'll email you when Regs.gov: Food and Drug Administration publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!